

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A mouse model of Guillain-Barré syndrome obtained by immunizing a homozygous FcγRIIB gene deficient mouse with GQ1b ganglioside, wherein said mouse model develops peripheral neuropathy leading to paralysis of its tail and hind legs and elevated levels of antibody titer against GQ1b occurs.
2. (Currently amended) ~~[[A]] The mouse model of Guillain-Barré syndrome~~ according to claim 1, wherein Guillain-Barré syndrome is Fisher syndrome.
- 3-5. (Cancelled)
6. (Currently amended) A screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome comprising,
 - (i) administering a test substance to the mouse model of claim 1 or 2; ~~3, and observing and assessing the degree of symptoms of Guillain-Barré syndrome and/or Fisher syndrome in the~~
 - (ii) measuring the level of anti-GQ1b antibody present in said mouse model of the syndrome; ~~[[,]] and~~

(iii) observing said mouse model of the syndrome for the degree of peripheral neuropathy wherein paralysis of the tail and hind legs occurs; wherein said test substance has a therapeutic effect against Guillain-Barré syndrome and/or Fisher syndrome when the level of anti-GQ1b antibody and the degree of peripheral neuropathy are decreased.

7. (Cancelled)

8. (Currently amended) A therapeutic agent obtained by [[the]] a screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome comprising, according to claim 6

(i) administering a test substance to the mouse model of claim 1 or 2;

(ii) measuring the level of anti-GQ1b antibody present in said mouse model of the syndrome; [[.]] and

(iii) observing said mouse model of the syndrome for the degree of peripheral neuropathy wherein paralysis of the tail and hind legs occurs; wherein said test substance has a therapeutic effect against Guillain-Barré syndrome and/or Fisher syndrome when the level of anti-GQ1b antibody and the degree of peripheral neuropathy are decreased.

9. (Cancelled)